Fig. 2.
Effect of receptor-selective antagonists on SFLLRN- and GYPGKF-induced inhibition of adenylyl cyclase in platelets from a P2Y12-defective patient.
Effects of PAR1 and PAR4 on cAMP accumulation were measured in P2Y12-deficient human platelets. Conditions were identical to those used in Figure 1 except that P2Y12-deficient human platelets were used along with AR-C69931MX and 10 μM yohimbine. The experiment was repeated twice using platelets from the same patient.
